Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

Prostate. 1998 Jul 1;36(2):129-38. doi: 10.1002/(sici)1097-0045(19980701)36:2<129::aid-pros8>;2-d.


Background: Most strategies in cancer immunotherapy are aimed at the induction of a strong cellular immune response against the tumor. Particularly, CD8+ T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors.

Methods: We used a population of peripheral blood-derived antigen-presenting cells (APC), containing dendritic cells (DC), to generate prostate tumor-specific CD8+ T cells. Selected peptides from prostatic acid phosphatase (PAP), a prostate tissue-specific antigen, were shown to bind HLA-A2. A high-affinity peptide was used to generate peptide-specific CD8+ cytolytic T lymphocytes (CTL) from the peripheral blood of healthy donors.

Results: The obtained PAP-peptide-specific CTL lysed peptide-coated target cells, vaccinia-infected target cells, and HLA-A2-positive prostate-tumor cells in vitro in an antigen-specific manner.

Conclusions: Our results indicate that CTL precursors to the PAP gene product exist and could be potentially recruited to elicit an antitumor response. Thus, PAP is a suitable antigen for inclusion in prostate cancer vaccines.

MeSH terms

  • Acid Phosphatase / chemistry
  • Acid Phosphatase / immunology*
  • Antigen-Presenting Cells / immunology*
  • CD8-Positive T-Lymphocytes / immunology*
  • Cytotoxicity, Immunologic
  • Dendritic Cells / immunology
  • HLA-A2 Antigen / metabolism
  • Humans
  • Male
  • Peptide Fragments / chemistry
  • Peptide Fragments / immunology*
  • Prostate / enzymology*
  • Prostatic Neoplasms / immunology*


  • HLA-A2 Antigen
  • Peptide Fragments
  • Acid Phosphatase